Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04861467 | Unknown Phase 2

• 1 other identifier: CATCH
• Study Type: interventional
• Target: 155
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.

Conditions

HNSCC

Keywords

Immunotherapy; Chemoradiation

Outcome Measures

Primary Outcomes (1)

• median progression-free survival(in accordance with RECIST1.1)

  mPFS is the median time from the date of randomization to the date of first record of disease progression or death.

  Up to 3 years

Secondary Outcomes (6)

• 1 year progression-free survival rate

  1 year from the the date of randomization

• overall survival

  Up to 3 years

• objective response rate

  Up to 3 years

• disease control rate

  Up to 3 years

• time to progression

  Up to 3 years

Other Outcomes (1)

• event-free survival in exploration group

  Up to 3 years

Study Arms (3)

Experimental: Camrelizumab

EXPERIMENTAL

camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)

Drug: Camrelizumab

observation

NO INTERVENTION

observation after Chemoradiation

Exploration：Camrelizumab

EXPERIMENTAL

camrelizumab for maintenance after chemoradiation( evaluation results：CR)

Drug: Camrelizumab

Interventions

Camrelizumab DRUG

IV

Experimental: Camrelizumab; Exploration：Camrelizumab

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Who have histologic or cytologic confirmation of head and neck squamous cell carcinoma in the mouth, oropharynx (p16-), hypopharynx, or larynx.
• Local advanced head and neck squamous cell carcinoma diagnosed as stage III-IVa by AJCC 8
• Except for the prescribed radical radiotherapy and chemotherapy regimen, there has been no previous treatment for LA-HNSCC systemic antitumor or local radical therapy (allowing the prescribed induction chemotherapy regimen before radical radiotherapy and chemotherapy)
• days after radical radiotherapy and chemotherapy (radiotherapy and chemotherapy (±7 days) did not show disease progression, and consideration was given within 28 days after curative effect evaluation
• Clinically assessable lesions according to RECIST1.1,(lesion length ≥10 mm or lymph node short diameter ≥15 mm)
• The age at which informed consent is signed is 18-70 years, male and female
• KPS score ≥80 percent
• Estimated lifetime ≥6 months
• The function of important organs meets the following requirements (excluding the use of any blood components and cytokines within 14 days):
• Normal bone marrow reserve function: WBC≥3.0×10\^9/ L, NEUT≥1.5×10\^9/ L, PLT≥80×10\^9/ L, Hb≥90g/L Normal renal function or SCr≤1.5 times normal upper limit (ULN) or Ccr≥50 ml/min ; Normal liver function or TBIL≤1.5 times the upper limit of normal value (ULN); AST or ALT level 2.5 times the upper limit of normal value (ULN);
• Ability and willingness to follow research and follow-up procedures
• Men and women of childbearing age must agree to adequate contraception throughout the study period and within 6 months after treatment
• The subjects volunteered to join the clinical study and signed informed consent, good compliance and follow-up

You may not qualify if:

• Have received any systemic anti-tumor therapy against the target lesion
• Previous experience in head and neck radiotherapy
• Previous immunotherapies including anti PD-1/PD-L1, anti CTLA-4, etc
• Subjects who received anti-tumor vaccines or other immunomodulatory drugs (e.g. interleukin-2, thymosin, Lentinus edodes polysaccharide, etc.) within 1 month prior to joining the group, or who received live attenuated vaccines
• Subjects who had been systematically treated with corticosteroids (prednisone or other equivalent hormones \>10 mg/ days) or other immunosuppressants within 1 month of entry. To allow inhaled or local use of corticosteroids in the absence of active autoimmune disease, as well as adrenocorticotropic replacement therapy ≤10 days mg/ dose of prednisone
• Pleural effusions, pericardial effusions or ascites requiring drainage, or serosal effusions for treatment within 2 weeks prior to group entry
• No active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary, vasculitis, nephritis, hyperthyroidism, hypothyroidism) may be included
• Subjects with severe infection within 1 month prior to admission, including, but not limited to, infection complications requiring hospitalization, bacteremia, severe pneumonia, etc. Subjects with any active infection, or unexplained fever \>38.5℃ during screening, prior to first administration
• Severe cardiovascular disease: grade II myocardial ischemia or myocardial infarction, uncontrolled arrhythmia; grade III \~ IV cardiac insufficiency, or echocardiography indicated that left ventricular ejection fraction (LVEF)\<50%;
• The subjects were treated with bronchiectasis and other systemic treatments. Asthma control was unsatisfactory and could not be included (asthma was completely alleviated in childhood and included without any intervention in adults)
• HIV infection or known AIDS, active hepatitis B (HBV DNA≥500 IU/ml), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower detection limit of the analytical method) or combined with hepatitis B and hepatitis C infection;
• Subjects with a history of other malignancies within five years (except complete treatment of skin cancer with cervical or basal cell carcinoma or squamous cell carcinoma in situ)
• Patients with a clear history of allergies may be allergic to, or intolerant to Camrelizumab

Sponsors & Collaborators

• Chinese Academy of Medical Sciences: lead

Study Sites (1)

Cancer hospital, Chineses Academy of Medical Sciences

Beijing, 100021, China

Location

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

camrelizumab

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Study Officials

• Junlin Yi

  Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Junlin Yi

CONTACT

13661217998; yijunlin1969@163.com

Ye Zhang

CONTACT

010-87787625; drzye1983@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 22, 2021
• First Posted: April 27, 2021
• Study Start: June 1, 2021
• Primary Completion: July 31, 2025
• Study Completion: December 31, 2025
• Last Updated: April 27, 2021

Record last verified: 2021-03

Locations

CN (1)